UBS Maintains Buy on Moderna, Raises Price Target to $151
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Buy rating on Moderna (NASDAQ:MRNA) and raises the price target from $143 to $151.
May 07, 2024 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Eliana Merle maintains a Buy rating on Moderna and raises the price target from $143 to $151.
The increase in the price target by UBS reflects a positive outlook on Moderna's stock, suggesting potential upside. This could lead to increased investor confidence and a possible short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100